BioSpace News Archive

Centessa Pharmaceuticals plc today announced positive topline results from the Phase 2a part of AP-0101, the six-month repeat dose portion of its ongoing first-in-human proof-of-concept study evaluating SerpinPC in severe hemophilia A and B patients.

Mind Medicine is pleased to announce that its Chief Medical Officer, Daniel R. Karlin , MD MA, will co-chair the 8th annual Mobile in Clinical Trials Conference , which will be held virtually on September 27, 2021 and is a partner program to the 2021 DPharm Conference.

Ventec Life Systems announced the addition of Erika Laskey as the Chief Commercial Officer for the company and member of the new executive leadership team.

Soligenix, Inc. announced today that the Office of Orphan Products Development of the United States (U.S.) Food and Drug Administration (FDA) has granted orphan drug designation to the active ingredient hypericin for the treatment of T-cell lymphoma, extending the target population beyond cutaneous T-cell lymphoma (CTCL) as previously granted.

Clover Biopharmaceuticals, Ltd. today announced that its wholly-owned subsidiary, Zhejiang Clover Biopharmaceutical, Inc., received a Pharmaceutical Manufacturing Permit from the Zhejiang Medical Products Administration

Apexigen, Inc., a clinical-stage biopharmaceutical company focused on discovering and developing a new generation of antibody therapeutics for oncology, today announced the appointment of Frank J. Hsu, M.D., as Chief Medical Officer, effective immediately

BrainsWay Ltd., a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, announced that Christopher von Jako, Ph.D., President and Chief Executive Officer, will present and participate in one-on-one investor meetings at two investment conferences during the month of September.

Enlivex Therapeutics Ltd. today announced that Company management will present a corporate overview at the H.C. Wainwright 23rd Annual Global Investment Conference, being held virtually September 13-15, 2021.

Erasca, Inc., a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, announced dosing of the first patient in the HERKULES-2 Phase 1b/2 trial evaluating ERAS-007 in combination with various agents in patients with advanced non-small cell lung cancer.

Vaccitech plc today announced that Bill Enright, Chief Executive Officer, will be presenting at the following investment conferences in September. Event: Morgan Stanley Healthcare Conference 2021